These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6673488)

  • 1. Amyloid-related serum protein (SAA) as an indicator of lung infection in cystic fibrosis.
    Marhaug G; Permin H; Husby G
    Acta Paediatr Scand; 1983 Nov; 72(6):861-6. PubMed ID: 6673488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients.
    Smith JW; Colombo JL; McDonald TL
    J Clin Lab Anal; 1992; 6(4):219-24. PubMed ID: 1403341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Paediatr; 1992 Mar; 81(3):227-30. PubMed ID: 1511195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
    Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
    Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment.
    Schiøtz PO; Jørgensen M; Flensborg EW; Faerø O; Husby S; Høiby N; Jacobsen SV; Nielsen H; Svehag SE
    Acta Paediatr Scand; 1983 Mar; 72(2):283-7. PubMed ID: 6340415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardisation of the quantitation of serum amyloid A protein (SAA) in human serum.
    Godenir NL; Jeenah MS; Coetzee GA; Van der Westhuyzen DR; Strachan AF; De Beer FC
    J Immunol Methods; 1985 Nov; 83(2):217-25. PubMed ID: 4056404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases.
    Nakayama T; Sonoda S; Urano T; Yamada T; Okada M
    Clin Chem; 1993 Feb; 39(2):293-7. PubMed ID: 8381732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum amyloid protein SAA, C-reactive protein and lysozyme in leprosy.
    Scheinberg MA; Masuda A; Benson MD; Mendes NF
    Int J Lepr Other Mycobact Dis; 1979 Jun; 47(2):133-7. PubMed ID: 572349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-related serum protein (SAA) during and after pregnancy in healthy women and women with rheumatic disease.
    Ostensen M; Marhaug G; Husby G
    Acta Pathol Microbiol Immunol Scand C; 1985 Feb; 93(1):1-5. PubMed ID: 3984747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of the serum amyloid A protein (SAA) in normal persons of different age groups.
    Hijmans W; Sipe JD
    Clin Exp Immunol; 1979 Jan; 35(1):96-100. PubMed ID: 428149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of serum amyloid A protein and C-reactive protein in disease.
    Maury CP
    Clin Sci (Lond); 1985 Feb; 68(2):233-8. PubMed ID: 3871381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease.
    Raynes JG; Cooper EH
    J Clin Pathol; 1983 Jul; 36(7):798-803. PubMed ID: 6863571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis.
    de Beer FC; Nel AE; Gie RP; Donald PR; Strachan AF
    Thorax; 1984 Mar; 39(3):196-200. PubMed ID: 6710428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
    Padoan R; Cambisano W; Costantini D; Crossignani RM; Danza ML; Trezzi G; Giunta A
    Pediatr Infect Dis J; 1987 Jul; 6(7):648-53. PubMed ID: 3302917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease.
    Uhde M; Ajamian M; Li X; Wormser GP; Marques A; Alaedini A
    Clin Infect Dis; 2016 Dec; 63(11):1399-1404. PubMed ID: 27585799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of serum amyloid-related protein SAA, C-reactive protein, and beta 2-microglobulin as markers of renal allograft rejection.
    Maury CP; Teppo AM
    Clin Nephrol; 1984 Dec; 22(6):284-92. PubMed ID: 6441659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.